ATS 2019

Women are more likely to be symptomatic, have greater odds of frequent, severe acute exacerbations.

Patients with pulmonary arterial hypertension experienced a significant improvement in World Health Organization Functional Class when transitioned from a phosphodiesterase type 5 inhibitor to riociguat.

Compared with standard of care tests and most clinical signs, the molecular bacterial load assay demonstrated higher sensitivity and more rapid turnaround times for monitoring tuberculosis treatment.

Combination treatment with ambrisentan and tadalafil is associated with a reduced mortality risk profile in patients with scleroderma-associated pulmonary arterial hypertension.

Umeclidinium improved all lung function measures compared with salmeterol in patients with COPD who were naive to maintenance therapy or who were treated with a single maintenance bronchodilator.

In patients with pulmonary arterial hypertension, factors that affect prognosis but not treatment response included age, gender, and connective tissue disease-PAH etiology.

When used as needed, the combination of budesonide-formoterol was found to be superior to albuterol for the prevention of asthma exacerbations in patients with mild asthma.

Researchers examined whether obesity is a factor in the mortality of patients with acute respiratory failure that requires intubation.

Benralizumab has been found to be associated with a reduction in oral corticosteroid (OCS) use while maintaining asthma control for patients with OCS-dependent severe asthma.

Individuals with moderate to very severe COPD and cardiovascular risk factors did not have an increased risk for all-cause mortality or major adverse cardiovascular event occurrence with the use of aclidinium.